valcyte主要治什么？

What kind of medicine is it? Which patients is it suitable for? Valcyte is an oral anti-cytomegalovirus infection drug developed by Roche of Switzerland and launched in my country in 2006. It is suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients.

For oral use, the recommended induction dose for the treatment of cytomegalovirus retinitis is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily. Valcyte agent should not be broken or crushed.

  Common side effects while taking valcyte (>10%): Cardiovascular: hypertension (12% to 18%); Central nervous system: headache, insomnia; Gastrointestinal: diarrhea, nausea (8%-30%), vomiting, abdominal pain (15%); Hematology and tumors: anemia (<31%), thrombocytopenia (<22%), neutropenia; Immune: graft rejection (24%); Muscle and bone: tremor ; Ophthalmology: Retinal detachment (15%); Renal: Increased serum creatinine; Others: Fever (9% to 31%). Side effects produced during taking valcyte usually diminish slowly as the medication is stopped.

Valcyte is well absorbed from the gastrointestinal tract and rapidly metabolized to ganciclovir in the small intestinal wall and liver. The absolute bioavailability of ganciclovir converted from valganciclovir is approximately 60%. Use with caution in patients with impaired renal function; dose adjustment required. Acute renal failure may occur in elderly patients with or without renal impairment; elderly patients should be used with caution and dosage adjustments based on renal function. The above are the indications, I hope it can help everyone.